Danaher Corp

Danaher delivered a strong second quarter, posting adjusted diluted EPS of $1.80 against a consensus estimate of $1.64, a beat of 9.74%, while revenue of $5.94 billion edged past expectations by 1.79% and grew 3.4% year over year. The standout driver was Biotechnology, where total sales climbed 8.0% as the segment's recovery gained clear momentum, offsetting a softer Life Sciences unit that recorded a 2.5% core revenue decline and absorbed a $432 million pretax trade name impairment charge. On a GAAP basis, that impairment, combined with elevated SG&A expenses, pulled net income down to $555 million from $907 million a year ago, underscoring how much the adjusted figure relies on stripping out non-recurring items. Free cash flow remained healthy at $1.09 billion, reinforcing the operational resilience that has drawn attention from analysts who see the stock trading at a potential discount to intrinsic value. Looking ahead, management raised full-year 2025 adjusted EPS guidance to $7.70 to $7.80 and maintained approximately 3% core revenue growth, signaling measured confidence despite a fluid macro backdrop.